THE EFFECTS OF ACE-I AND ARB ON PERITONEAL ALBUMIN LOSS AND SERUM ALBUMIN LEVELS IN PERITONEAL DIALYSIS PATIENTS

Year 2003, Volume: 16 Issue: 2, 103 - 106, 03.12.2016

Betül Öğütmen Serhan Tuğlular Emel Akoğlu Çetin Özener

Abstract

Objective: Anti-proteinuric effects of angiotensin converting enzyme inhibitors (ACE-I) and angiotensin receptor blockers (ARB) have been established in various renal diseases. However, the effects of ACE-I and ARB on the permeability of peritoneal membrane are unknown and the effect of ACE-I and ARB use on peritoneal permeability in patients undergoing continuous ambulatory peritoneal dialysis has not been studied.
Methods: Fifty non-diabetic patients with high peritoneal permeability, who had been on a regular peritoneal dialysis (PD) treatment for at least one year, were included in the study. The patients were prospectively randomized either fosinopril 10 mg/day p.o (n=25) (group 1) or valsartan 80 mg/day p.o (n=25) (group 2) for 12 months. All patients received standard 35- cal/kg/day diets with 1,2-g/kg/day protein intake and strict salt restriction. All patients were on standard PD program (2 L; 1.36%, 4
exchanges/day). Annual mean serum albumin level, calculated from the monthly serum albumin level and peritoneal albumin values obtained from the dialysate after 8 hours, dwell on two occasions 6 months apart were measured twice yearly.
Results: A significant increase in the serum albumin values, (3.68±0.56 g/dl vs. 3.94±0.46 g/dl, p<0.0001) a significant decrease in peritoneal fluid albumin values (9.06±2.65 g/dl vs. 7.08±1.43 g/dl, p<0.01) were observed in the ACE-I group following the treatment. While no significant change (3.75±0.48 g/dl vs. 3.87±0.37 g/dl, p>0.05) was observed in the serum albumin values, a significant decrease (8.62±3.87 g/dl vs. 5.84±2.94 g/dl, p<0.01) was obtained in peritoneal fluid albumin values for the ARB group.
Conclusion: At the end of the study a significant decrease was observed in the peritoneal protein values for patients on ACE-I and ARB.
Key Words: Peritoneal dialysis, Angiotensin converting enzyme inhibitor, Angiotensin receptor blocker and albumin

References

• Peterson JC, Adler S, Burkart JN, et al.: Blood pressure control, proteinuria, and the progression of renal disease: the Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754-762
• Bidani AH, Griffin HA, Picken M, Lansky DM: Continuous telemetric blood pressure monitoring and glomerular injury in the rat remnant kidney model. Am J Physiol, 1993; 265: P391-F398
• Gruppo Italiano Di Studi Epidemiologici in Mefrologia (GISEH): Randomized placebo- controlled trial of effect of ramipril on decline
• 0 5
• Betül Ogütmen, et al.
• in glomerular filtration rate and risk of terminal renal failure in proteinuric, nondiabetic nephropathy Lancet 1997;349:1857- 1863.
• Border WA, Noble NA. TGF-J3 in kidney fibrosis: a target for gene therapy. Kidney Int 1997;51:1388-1396.
• Peters ft, Border WA, Noble NA.: Targeting TGP- jS overexpression in renal disease: maximizing the antifibrotic action of angiotensin 11 blockade. Kidney Int 1998; 54:1570-1580.
• Nielsen S, Dollerup J, Nielsen B, Jensen HA, Plogensen CE: Losartan reduces albuminuria in patients with essential hypertension: An enalapril controlled 3 months study. Nephrol Dial Transplant 1997:2:19-23.
• Chan JC, Critchley JA, Tomlinson B, Chan TY, Cockram CS. Antihypertensive and anti- albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin- dependent diabetes mellitus. Am J Nephrol 1997,17:72-80.
• Gansevoort RT, De Zeeuw D, De Jong Pe. Is the antiproteinuric effect of ACE inhibition mediated by interference in the renin- angiotensin system? Kidney Int 1994:45:861- 867.
• Toto R, Shultz P, Raij L, et al: Efficacy and tolerability of losartan in hypertensive patients with renal impairment: Collaborative Group. Hypertension 1998;31 -.684-691.
• Plum J, Bünten B, Nemeth R, Grabensee B: Effects of the angiotensin II antagonist vaisartan on blood pressure, proteinuria, and renal hemodynamics in patients with chronic renal failure and hypertension. J Am Soc Nephrol 1998;9:2223-2234.
• Bokemayer D, Regulation of mitogen-activated protein kinase phosphatase-1 in vascular smooth muscle cells. Hypertension 1998; 32:661-667.
• ¡2. Murasawa S, Role of calcium-sensitive tyrosine kinase Pyk2/CAK-beta/RAPTK in Ang ll-induced Ras/ERK signaling. Hypertension 1998;32:668-675.